PARP1 and cancer: A Phase I clinical trial of patients with solid tumors using MK-4827 was shown to have favorable pharmacokinetics, inhibited PARP activity effectively, is well tolerated and has anti-tumor activity in carriers of BRCA1 and BRCA2 mutations and patients with sporadic cancers (144).